Paper Details

  1. Home
  2. Paper Details

Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study.

Author: , BertrandMichel E, DeckersJaab W, FerrariRoberto, FoxK M, RemmeWilhelm J, SimoonsMaarten L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the effects of adding perindopril to long-term treatment with calcium-channel blockers (CCB) in patients with stable coronary artery disease (CAD). The results suggest that perindopril may have a synergistic effect with CCB in secondary prevention.
Paper Details　
Original Abstract of the Article :
The purposes of the study were to determine the effects of addition of perindopril to long-term continuous treatment with calcium-channel blocker (CCB) on cardiac outcomes in the stable coronary artery disease (CAD) population of EUROPA and to explore the presence of synergy between perindopril and ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ahj.2009.12.042

データ提供：米国国立医学図書館（NLM）

Examining the Synergy of Perindopril and Calcium-Channel Blockers in Coronary Artery Disease

In the realm of cardiovascular medicine, researchers are constantly searching for new and effective strategies to combat coronary artery disease (CAD). This study delves into the potential benefits of combining perindopril, an ACE inhibitor, with calcium-channel blockers (CCBs) for long-term treatment of stable CAD. Using a post-hoc analysis of the EUROPA study, the researchers aimed to determine if this combination therapy could improve cardiac outcomes and investigate whether there is a synergistic effect between these two medications. They utilized a rigorous approach, carefully analyzing data from a large-scale clinical trial.

A Deeper Look at the Findings

This study's results provide valuable insights into the potential benefits of combining perindopril with CCBs for the secondary prevention of cardiovascular events in patients with stable CAD. The research suggests that this approach might be particularly effective in minimizing the risk of heart attacks and other cardiovascular problems.

Implications for Patient Care

These findings have significant implications for patients with stable CAD, highlighting the potential benefits of combining perindopril with CCBs in their treatment regimens. It's important for patients to discuss their individual risk factors and treatment options with their healthcare providers to determine the most appropriate approach.

Dr.Camel's Conclusion

Just like a camel can navigate the vast and unforgiving desert, researchers are diligently searching for ways to improve patient care in the often-difficult landscape of cardiovascular disease. This study offers promising insights into the potential benefits of combining perindopril and CCBs for patients with stable CAD, emphasizing the need for ongoing research and individualized treatment approaches.

Date :
  1. Date Completed 2010-05-24
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

20435188

DOI: Digital Object Identifier

10.1016/j.ahj.2009.12.042

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.